BCL2 and hepatocellular carcinoma: Additionally, FH535 is a potent therapeutic inhibitor that, upon combination with Sorafenib, exerts synergistic inhibition of proliferation and induction of apoptosis via enhancing cleaved poly (ADP-ribose) polymerase (PARP), inhibiting cyclin D1, Bcl-2, survivin, and c-MYC levels and reducing both mitochondrial respiration and glycolytic rates to disrupt the bioenergetics of HCC/LCSC cells [128,129].